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Sulfonation catalyzed by sulfotransferase enzymes
plays an important role in chemical defense mechanisms
against various xenobiotics but also bioactivates carcino-
gens. A major human sulfotransferase, SULT1A1, metab-
olizes and/or bioactivates many endogenous compounds
and is implicated in a range of cancers because of its
ability to modify diverse promutagen and procarcinogen
xenobiotics. The crystal structure of human SULT1A1 re-
ported here is the first sulfotransferase structure com-
plexed with a xenobiotic substrate. An unexpected find-
ing is that the enzyme accommodates not one but two
molecules of the xenobiotic model substrate p-nitrophe-
nol in the active site. This result is supported by kinetic
data for SULT1A1 that show substrate inhibition for this
small xenobiotic. The extended active site of SULT1A1 is
consistent with binding of diiodothyronine but cannot
easily accommodate -estradiol, although both are known
substrates. This observation, together with evidence for a
disorder-order transition in SULT1A1, suggests that the
active site is flexible and can adapt its architecture to
accept diverse hydrophobic substrates with varying sizes,
shapes and flexibility. Thus the crystal structure of
SULT1A1 provides the molecular basis for substrate inhi-
bition and reveals the first clues as to how the enzyme
sulfonates a wide variety of lipophilic compounds.
Sulfonation is a widely distributed biological reaction cata-
lyzed by members of the supergene family of enzymes called
sulfotransferases (SULTs).1 SULTs utilize the sulfonate donor
3-phosphoadenosine 5-phosphosulfate (PAPS) to catalyze sul-
fonation, yielding PAP as the desulfonated product of the re-
action. These enzymes modify the biological activities of a
diverse range of compounds including neurotransmitters, hor-
mones, and drugs. The reaction aids excretion of foreign chem-
icals but, in some cases, causes bioactivation of carcinogens and
mutagens (1–3). SULTs are the focus of intense research in the
fields of cancer, drug metabolism, and pharmacogenetics be-
cause genetic variation, particularly in isoenzyme SULT1A1,
may predispose to lung cancers (4), protect against colorectal
cancers (5), and affect the age of onset in breast cancer (6).
To date, five distinct mammalian gene families for cytosolic
SULTs (SULTs 1–5) have been identified (7), although SULT3
and SULT5 have not been found in humans (8). The most
extensive group of the human cytosolic SULTs is the SULT1
family, which includes SULTs 1A1, 1A2, 1A3, 1B1, 1C1, 1C2,
and 1E1. Each SULT has distinct substrate preferences but
may also exhibit broad and overlapping substrate specificity to
span the diversity of chemicals requiring sulfonation. For ex-
ample, SULT1A3 catalyzes dopamine sulfonation but also ac-
cepts p-nitrophenol (pNP) with lower affinity (9, 10). SULT1A1,
which shares 93% identity with SULT1A3, also sulfonates do-
pamine and pNP but with the reverse preference, and in addi-
tion it can sulfonate a wide range of hydrophobic molecules
(Fig. 1) including xenobiotics and endogenous substrates 3,3-
diiodothyronine (T2) (11, 12) and 17-estradiol (E2) (3, 13).
SULT crystal structures have been determined for mouse
estrogen SULT1E1 complexed with PAP/E2 (Protein Data
Bank (PDB) codes in parentheses) (1AQU), PAP (1AQY), or
PAP/vanadate (1BO6) (14); human estrogen SULT1E1 com-
plexed with PAPS (1HY3) (15); human dopamine SULT1A3
complexed with SO4
2 (1CJM) (16) or PAP (10); human hydrox-
ysteroid SULT2A3 complexed with PAP (1EFH) (17); the SULT
domain of heparin sulfate-N-deacetylase complexed with PAP
(1NST) (18); and human dehydroepiandrosterone sulfotrans-
ferase (DEA-SULT) complexed with substrate (1J99) (19). All
of these structures incorporate a common PAPS binding region
and a variable substrate binding region. Of these, only the
mouse SULT1E1-PAP-E2 and the DEA-SULT structures were
determined in the presence of an acceptor substrate.
To gain an understanding of the substrate specificity of the
human SULT1A family, we have investigated the structures of
SULT1A1 and SULT1A3. The similarities and differences be-
tween SULT1A family members represent a good experimental
model with which to unravel the critical features that deter-
mine substrate preferences of cytosolic SULTs. Our approach
has involved the use of site-directed mutagenesis and x-ray
crystallographic studies of both SULT1A1 and SULT1A3. We
reported the first crystal structure of human SULT1A3 (16).
Although the substrate was not bound in the structure, with
the aid of site-directed mutagenesis and molecular modeling,
we and others have identified some of the residues involved in
substrate specificity of SULT1A3 (9, 10, 20).
We now report the crystal structure of human SULT1A1
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crystallized in the presence of PAP and pNP. This is the first
SULT crystal structure complexed with a xenobiotic substrate,
and unexpectedly it reveals two pNP molecules in the active
site. We show that at low concentrations of this substrate, the
kinetics exhibit slight nonhyperbolic behavior and that at high
concentrations the enzyme activity is inhibited. These kinetic
features are fully consistent with the structure that we have
determined. We also show that the endogenous ligand T2 can
bind within the substrate binding site in a flexed conformation
but that E2 cannot be as easily accommodated.
EXPERIMENTAL PROCEDURES
Expression, Purification, Enzyme Activity, and Crystallization—Hu-
man SULT1A1 cDNA incorporating an N-terminal hexahistidine tag
was expressed in Escherichia coli using a pET-28a() vector as de-
scribed previously (9, 16, 21). SULT1A1 was purified by TALON cobalt
affinity (Clontech Laboratories) and gel filtration chromatography and
then concentrated to 25 mg ml1 in 20 mM Tris, pH 8.0, and 10 mM
dithiothreitol. Protein purity was estimated to be above 95%
by SDS-PAGE.
Enzyme activity was determined by the method described by Foldes
and Meek (22). The reaction mixture contained 10 mM potassium phos-
phate, pH 7.0, 20 M [35S]PAPS, 0.1 g/ml SULT1A1, and varying
concentrations of the substrate (pNP 0.1–20 M) in a final volume of 500
l. Reactions were initiated by the addition of enzyme to the reaction
mixture, which was then incubated for 20 min at 37 °C. The reaction
was terminated by precipitation of enzyme and [35S]PAPS with 0.1 M
barium acetate, 0.1 M barium hydroxide, and 0.1 M zinc sulfate. The
incubation time and protein concentration used were chosen to be
within the linear range for product formation using pNP as the sub-
strate. Assays were performed in duplicate and corrected for back-
ground activity using a control with no substrate added. Radioactivity
of the sulfonated pNP was quantified using a liquid scintillation coun-
ter (Tri-Carb 2500, Packard).
Crystallization was carried out using hanging drop vapor diffusion.
Initial conditions were identified from Hampton Research commercial
screens and then optimized by incremental scanning around the initial
conditions. The final crystallization conditions are as follows. The pu-
rified protein was preincubated with 45 mM PAP and 5 mM pNP on ice
for 30 min. Thereafter, 1 l of reservoir solution (0.1 M Tris-HCl, pH 8.0,
20% polyethylene glycol 4000) was mixed with 1 l of protein solution
on the coverslip, placed over the well containing the reservoir solution,
and incubated at 20 °C. Orthorhombic crystals (size  0.5  0.3  0.2
mm) appeared 3–4 days after microseeding in 0.1 M Tris-HCl, pH 8.0,
20% polyethylene glycol 4000.
Diffraction Data Measurement—X-ray diffraction data were meas-
ured on an R-AXIS IV/RU-200 system with Osmic Blue mirror
optics. Crystals were mounted in quartz capillary tubes, and diffraction
data to 1.9 Å resolution were measured at 17 °C. An oscillation range of
1°, an exposure time of 3 min, and a crystal-to-detector distance of 100
mm were used. The data were integrated, merged, and scaled using the
software package Crystal Clear (Rigaku Corp.).
Structure Determination and Refinement—Monomer A of mouse
SULT1E1 (48% sequence identity, PDB code 1AQU (14)) was used as
the search model for phasing by molecular replacement. The model was
generated by changing to alanine all residues with sequence differences
between SULT1A1 and mouse SULT1E1. The model included residues
7–64, 75–242, and 244–295 of mouse SULT 1E1. Rigid body refinement
of the molecular replacement solution in CNS software package (23)
gave R-factor and R-free values of 48.9 and 49.2%, respectively. Simu-
lated annealing, by Cartesian molecular dynamics, followed by re-
strained B-factor refinement improved these values to 35.8% and
38.7%, respectively. Several rounds of model building in O (24) and
refinement in CNS software package gave a final R-factor of 18.2% and
R-free of 20.5%. The final model includes all except the first seven
residues at the N terminus (there is no density for the additional
hexahistidine tag residues). The crystal structure includes bound PAP,
two pNP molecules, and 154 water molecules. Alternate conformations
are modeled for Glu13, Gln35, Val54, Met77, Asp156, Glu174, Glu246, and
Met260. The quality of the structure was assessed with PROCHECK
(25) and WHATCHECK (26). Coordinates and structure factors have
been deposited in the PDB with code 1LS6 (27).
Molecular Modeling—For structural comparison with SULT1A1, the
crystal structures of SULT1A3 (PDB code 1CJM (16)) and SULT1E1
(1AQU (14)) were used. For T2 (diiodothyronine) and E2 docking, PAPS
was modeled into the SULT1A1 structure based on the SULT1E1-PAPS
structure (PDB code 1HY3 (15)) and water and pNP molecules were
removed from the substrate binding site. T2 (or E2) was docked using
GOLD (28) with 10 genetic algorithm runs and default parameters. E2
was also modeled into SULT1A1 using the bound conformation of the
ligand in SULT1E1 (PDB code 1AQU). The ligand was oriented in the
SULT1A1 active site after superimposing the two protein structures
based on a structural alignment of active site residues within 5 Å of the
ligand. Solvent-accessible (Connolly) surfaces were calculated in In-
sightII using a radius of 1.4 Å. Figures were prepared using Molscript
(29), Raster3d (30), and InsightII (Accelrys).
RESULTS
The crystal structure of SULT1A1 (Fig. 2a) has been refined
to 1.9 Å (Table I) with excellent crystallographic and geometric
statistics. The structure incorporates the core / domain
found in all SULTs that forms a central 5-stranded parallel
-sheet surrounded on either side by helices. The SULT1A1
crystal structure is well ordered, with only the first 7 of 295
(2%) residues disordered. This is in stark contrast to the crystal
FIG. 1. Selection of compounds that are sulfonated by
SULT1A1 (3, 8, 9, 11, 12, 13, 37).
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structure of the apo form of the highly related SULT1A3 isoen-
zyme (PDB code 1CJM (10, 16)), which has 70 disordered
residues (23%). A structure-based sequence alignment of the
three SULT1 family members for which structures are now
known (SULT1A1, SULT1A3, and SULT1E1) is given in
Fig. 2b.
PAP Binding—The electron density for ligands bound at the
active site of SULT1A1 is shown in Fig. 3a. The binding mode
of PAP to the active site of SULT1A1 is similar to that de-
scribed previously for the interaction of PAP with mouse
SULT1E1 (14). Briefly, 5-phosphate positioning, thought to be
important for orienting the cofactor for in-line sulfuryl transfer
to substrate (10, 14, 15), is brought about by an intricate
network of interactions with the phosphosulfate binding (PSB)
loop (14) of the enzyme (45TYPKSGT51 in SULT1A1). The PAP
3-phosphate interacts with two conserved regions of sequence
(Fig. 2b), residues 257-RKG-259 from the GXXGXXK SULT
motif and residues Arg130 and Ser138. As in the SULT1E1
structure, the adenine ring forms stacking and T-shaped inter-
actions with the conserved residues Trp53 and Phe229 and is
stabilized by hydrogen bond interactions (between N-6 and
Thr227 and between N-3 and Tyr193).
Substrate Binding—An unanticipated finding revealed by
the crystal structure is the presence of two pNP molecules in a
large L-shaped substrate binding site in SULT1A1 (Fig. 3b).
pNP1 (average B-factor, 22 Å2) is bound in a catalytically com-
petent manner, and its phenol ring is oriented within the active
site in the same way that the E2 phenol ring is oriented in the
mouse SULT1E1 complex. As in the SULT1E1 structure,
Phe142 and Phe81 form a substrate access gate that permits
binding of planar substrates only at the catalytic site. The
phenol hydroxyl of pNP1 forms hydrogen bonds with side
chains of catalytic residues His108 and Lys106 and with a well
ordered water molecule (Fig. 3b). The nitro group interacts
with a water and forms van der Waals interactions with Val148,
Phe247, and Met248. pNP2 (average B-factor, 41 Å2) appears to
be more weakly bound; no interactions are formed with cata-
lytic residues, but the aromatic ring slots between the side
chains of Phe84 and Phe76, the nitro group interacts with a
water molecule, and van der Waals interactions are formed
between the molecule and side chains of Ile89 and Phe247.
The L-shaped substrate binding pocket that accommodates
both pNP1 and pNP2 is well ordered and very hydrophobic (Fig.
3b), incorporating predominantly aromatic residues (Phe76,
Phe81, Phe84, Phe142, His149, Phe247, Phe255, and Tyr240, Tyr169,
and Phe24; the last three residues are not shown in Fig. 3b for
purposes of clarity) and aliphatic residues (Ile89, Val148, Met248
and, not shown in Fig. 3b for clarity, Ile21, Met77, Val243, Pro90,
and Ala146). Seven of the 10 aromatic residues of the substrate
binding site are conserved in SULT1A3, with the other three
replaced either by other aromatic residues or by aliphatic res-
idues (Phe76 by Tyr, Phe84 by Val, and Phe247 by Leu). On the
other hand, whereas six of the eight aliphatic residues are
conserved as hydrophobic residues in SULT1A3, two of them
(Ile89 and Ala146) are replaced by glutamate residues. Residue
146 has already been investigated by site-directed mutagene-
sis. Thus, a single site mutant of SULT1A1 in which Ala146 is
replaced by glutamate (A146E) shows an 400-fold reduced
affinity for pNP (9). Further, a SULT1A3 mutant in which
Glu146 is replaced with the SULT1A1 residue, alanine (E146A),
exhibits SULT1A1-like substrate specificity, preferring pNP
over dopamine (9, 20, 31). These results suggest that the hy-
drophobic nature of the SULT1A1 binding site is critical for its
substrate binding and specificity.
Kinetics of pNP Sulfonation by SULT1A1—The kinetic im-
plications of the presence of two molecules of pNP in the
active site were investigated using a wide range of concen-
trations of the substrate (Fig. 4). The results show that there
is a slight deviation from Michaelis-Menten kinetics (Fig. 4a,
broken line) at low substrate concentrations, suggestive of
some positive cooperativity. However, the most pronounced
feature is substrate inhibition at concentrations above 2 M.
These kinetic properties are interpreted under the general
model described in Scheme 1. The enzyme can bind pNP at
site 1 or site 2, and occupancy of site 1 does not prevent
subsequent binding at site 2. There are two catalytically
competent species, ES1 and ES1S2, and these form product
with different efficiencies.
The catalytically competent species ES1 and ES1S2 form
enzyme-product complexes (EP and EPS2) with rate constants
of k1 and k2, respectively. Release of product from EP is direct
(dissociation constant  KP,) whereas release from EPS2 re-
quires prior release of pNP from site 2 (dissociation constant 
KPS2) (Scheme 1). This equation gives a good fit to the experi-
mental data, as shown by the solid lines in Fig. 4. Several
FIG. 2. Structure of human SULT1A1. a, human SULT1A1 C
trace colored from blue at the N terminus to red at the C terminus.
Secondary structural elements are depicted as coils for helices and
arrows for strands. Bound ligands are represented by spherical atomic
models (PAP, white; pNP1, dark gray; pNP2, light gray). Residue Phe247
is shown in a ball-and-stick representation (pink). b, structure-based
sequence alignment of human SULT1A1, human SULT1A3, and Mus
musculus SULT1E1. Secondary structural elements in SULT1A1 are
indicated by red (helix) or green (strand) bars above the sequence. PSB
indicates residues in the highly conserved PSB loop. Residues that are
not conserved are shown in red. Regions of sequences that are struc-
turally similar are highlighted with a yellow background. Disordered
residues in each structure are underlined.
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simpler alternative models were also tested, but these yielded
poorer fits to the data. Therefore, we conclude that the presence
of two molecules of pNP in the active site, as revealed by the
structure, represents a real property of SULT1A1 and that the
kinetic properties of the enzyme are explained by the influence
of occupancy of site 2.
Assuming that all binding steps are at equilibrium and that
[P]  0, the derived rate equation is
v ETS]	k1KS1S2  k2[S])/	KS1KS1S2[S]KS1KS1S2(1/KS1  1/KS2)[S]
2)
(Eq. 1)
Equation 1 involves five kinetic constants but can define only
four independent parameters (Equation 2) because of internal
redundancy.
v V
[S]	K1  [S]/	K2K3  [S]K3  [S]2) (Eq. 2)
where V
  k2[E]T, K1  k1Ks1s2/k2, K2  1/(1/Ks1  1/Ks2), and
K3  Ks1Ks1s2(1/Ks1  1/Ks2).
Endogenous Ligands—The size and nature of the binding
pocket in SULT1A1 suggests that hydrophobic molecules much
larger than pNP can be accommodated. Other workers have
shown that SULT1A1 catalyzes sulfonation of thyroid hor-
mones such as T2 (11, 12). We therefore undertook docking of
T2 into the crystal structure of SULT1A1 and have identified a
catalytically competent binding conformation (Fig. 5a). In this
model, the 4-OH is oriented toward catalytic residues and the
two phenyl rings of T2 adopt an L-shaped conformation with
respect to each other, which enables each ring to occupy one of
the two pNP binding sites. However, this binding mode is only
TABLE I
Data measurement and refinement for SULT1A1:PAP:pNP crystal structure
Values in brackets refer to the highest resolution shell (1.90–1.97Å). r.m.s.d., root-mean-square deviation.
Data collection Refinement
Unit cell R-factorb (%) 18.2
a(Å) 72.8 R-freec (%) 20.5
b(Å) 124.0 No. of water molecules 154
c(Å) 44.5 Average B-factor (Å2) 25
, ,  (°) 90 Resolution range (Å) 20–1.9
Space group P21212 r.m.s.d. from ideal
No. of molecules in asymmetric unit 1 Bond length (Å) 0.007
Observations (I  0I) 82,261 Bond angle (°) 1.3
Unique reflections (I  0I) 31,483 Ramachandran statistics
Rsym (%)
a 4.1 (22.0) Residues in most favored region (%) 92.4
I/ (I) 8.6 (2.4) Residues in additionally allowed
region (%)
7.6
Completeness (%) 91.4 (63.8%) Residues in disallowed regions (%) 0
Mosaicity 0.38
a Rsym  I  I(I).
b R-factor  Fo  Fc/Fo.
c R-free is calculated from 10% of the data.
FIG. 3. SULT1A1 ligand binding. a,
stereo view of electron density (2Fo  Fc
at 1.1 ) at the active site of SULT1A1
showing the binding modes of PAP and
two molecules of pNP. The catalytic resi-
due His108 is also shown. b, stereo view of
the substrate binding site showing the hy-
drophobic nature of residues surrounding
the two pNP molecules. Ligands and res-
idues are depicted as ball-and-stick mod-
els, with atom-based coloring as follows:
nitrogen, dark blue; oxygen, red; phospho-
rus, magenta; sulfur, yellow; pNP1 car-
bon, orange; pNP2 carbon, blue; PAP car-
bon, green; enzyme carbon, gray. Bound
water molecules are shown as red spheres.
Residues not shown for clarity are Ile21,
Phe24, Met77, Pro90, Ala146, Tyr169, Tyr240,
and Val243.
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possible if Phe247 adopts a different (though still favorable)
rotamer conformation to prevent a steric clash with one of the
iodine atoms of the substrate (Fig. 5a).
SULT1A1 is also reported to sulfonate E2 (3, 13), albeit with
lower affinity than other substrates. E2 is a steroid and thus
incorporates four fused rings in an extended planar molecular
structure. We modeled E2 into the SULT1A1 binding site using
the binding mode identified in the SULT1E1-PAP-E2 structure
(14). However, E2 cannot be accommodated in this same way in
the crystal structure of SULT1A1 (Fig. 5b) because a large
number of unfavorable interactions and steric clashes occur
between the E2 C/D rings and SULT1A1 even with the altered
rotamer conformation for Phe247. We also performed docking
studies using GOLD but could not identify a favorable binding
mode for E2. The unfavorable interactions that are formed
involve residues in two loops (residues 146–154 between 6
and 7 and residues 84–90 just preceding 4; Fig. 5b) that close
over the hydrophobic active site of SULT1A1 more tightly than
they do in the SULT1E1 crystal structure (Fig. 5c). This re-
stricts the space available for ligands that bind in an extended
conformation in SULT1A1 (Fig. 5d) compared with SULT1E1
(Fig. 5e).
How is it then that E2, a known substrate of SULT1A1, is
accommodated in the binding site? Because the fused ring
system of E2 is unlikely to adopt a bent conformation to match
the L-shaped binding site in the crystal structure, E2 sulfon-
ation could occur only if there were a conformational change in
SULT1A1 that extended the accessible space for multiple fused
ring molecules. Thus, the SULT1A1 substrate binding site
must be sufficiently plastic to accept both flexible (bent) and
rigid (extended) ring systems. The relative Km values for E2 (85
M (13)) and T2 (0.5 M (11)) suggest that binding of the
extended fused ring system of E2 by SULT1A1 occurs at an
energy cost; this could be due to the conformational rearrange-
ment required for the enzyme to accept the steroid. The
changes that would be required to allow E2 binding would most
likely involve movement of the two loops described above. We
are undertaking co-crystallization trials of SULT1A1-E2 and
SULT1A1-T2 to investigate experimentally how the enzyme
can accommodate both flexible and rigid multi-ring substrates.
Comparison with SULT1A3 and SULT1E1—At the time of
this writing, the crystal structures of three SULT1 family
members are known, those of estrogen sulfotransferase
(SULT1E1), dopamine sulfotransferase (SULT1A3), and car-
cinogen-converting sulfotransferase (SULT1A1, reported here).
SULTs 1A1 and 1A3 have the highest sequence identity (93%),
and yet only 74% of SULT1A1 backbone residues can be super-
imposed with SULT1A3 (PDB code 1CJM) (212 of the 288
SULT1A1 structurally characterized C atoms, root mean
square deviation 0.88 Å). By contrast, 93% of residues can be
superimposed between SULT1A1 and SULT1E1 (PDB code
1AQU) (269 C atoms, root mean square deviation 1.1 Å) al-
though they share only 48% sequence identity. The reason is
that 23% of residues in the apoSULT1A3 structure are disor-
dered, whereas very few residues are disordered in the
SULT1A1 and SULT1E1 structures (Fig. 6). Both the
SULT1A1 and SULT1E1 structures were determined in the
presence of cofactor product and substrate. Most of the 68
disordered residues of SULT1A3 correspond to substrate bind-
ing regions of SULT1A1 and SULT1E1. These residues adopt
very similar conformations in the two ligand-bound enzyme
structures (Fig. 6) and make important interactions with both
cofactor and substrate ligands (Fig. 3).
FIG. 4. Effect of pNP concentrations on the activity of
SULT1A1. Open and closed symbols show the results from two inde-
pendent experiments. Each data point is the mean of duplicate or
triplicate assays, and the standard deviation is contained within the
dimensions of the symbols. Panel a shows pNP concentrations up to 1.5
M. The lines represent a fit to these data of the Michaelis-Menten
equation (broken line) (Vm  859  102 nmol min
1 mg1, Km  1.0 
0.2 M) or Equation 2 (solid line) (V
  118  18 nmol min
1 mg1, K1
 9.0  2.0 M, K2  16.2  1.4 M, and K3 fixed at 0.1 M). The
residuals for each fit are shown above the main graph, with squares and
circles representing the deviations from the Michaelis-Menten equation
and Equation 2, respectively. Panel b shows the activity of SULT1A1 as
a function of pNP concentrations up to 20 M, with the solid line defined
as described in a.
SCHEME 1. Kinetic model of SULT1A1 based on the enzyme
structure with two molecules of pNP in the active site. The
enzyme (E) can bind pNP at site 1 to give ES1 with a dissociation
constant of KS1 or at site 2 to give ES2 with a dissociation constant of
KS2. Occupancy of site 2 prevents pNP from binding to site 1, whereas
pNP at site 1 does not prevent subsequent binding at site 2, to
give ES1S2.
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DISCUSSION
Substrate inhibition has been reported previously for both
SULT1A1 (32, 33) and SULT1A3 (34) at high concentrations of
their preferred small molecule substrates. However, published
kinetic studies have generally assumed a Michaelis-Menten
model to explain catalysis by these two enzymes and have
therefore focused upon moderate substrate concentrations only
(35, 36). The crystal structure of SULT1A1 with two molecules
of pNP bound at the active site clearly shows how inhibition
occurs by this substrate. This is validated by our analysis of
SULT1A1 catalysis, which approximates Michaelis-Menten ki-
netics at low substrate concentrations, characterized by a hy-
perbolic curve (3, 35, 37, 38) but also exhibits substrate inhi-
bition at high concentrations of pNP. These kinetic properties
are consistent with the existence of two binding sites for pNP.
Substrate inhibition at high concentrations of pNP is due to
impeded catalysis when both binding sites are occupied. The
crystal structure of SULT1A1 represents the first sulfotrans-
ferase that binds two xenobiotic molecules in the substrate-
binding pocket, although an allosteric binding site has previ-
ously been postulated for E2 in mouse SULT1E1 (39) and for
substrate binding in human thyroid hormone sulfotransferase
(SULT1B1) (40). Furthermore, the recently reported structure
of DEA-SULT complexed with substrate (19) identifies two
alternate substrate binding orientations, one in a catalytic
binding mode and the other proposed to give rise to substrate
inhibition.
The binding of two molecules of pNP in the active site of
SULT1A1 also serves to highlight the large and very hydropho-
bic nature of the substrate binding region of this enzyme. The
20 residues that surround the two pNP molecules are all ali-
phatic (Ile, Val, Met, Pro, Ala) or aromatic (Phe, Tyr, His),
apart from the catalytic residue Lys-106. It is well known that
SULT1A1 can accept a wide assortment of molecules for sul-
fonation (Fig. 1). These include simple uncharged substituted
phenols (9), aromatic hydroxylamines, aromatic heterocyclic
hydroxylamines, polycyclic aromatic compounds (8), iodothy-
ronines (11, 12), and estrogens (3, 13). Thus, the substrate
binding site can accept small flat aromatic compounds, larger
L-shaped aromatics, and extended planar aromatic or aliphatic
ring systems. Together, the SULT1A1 crystal structure and our
modeling studies show how the substrate binding site can
interact with small aromatics and L-shaped aromatics but do
not explain easily how extended fused ring systems, such as E2,
FIG. 5. E2 and T2 binding. a, T2 (yellow) docked into the SULT1A1 active site, showing the solvent-accessible surface calculated with Phe247
in an alternate binding mode (pink). PAPS is shown in the cofactor binding site. For orientation, the bound conformations of pNP1 (orange) and
pNP2 (blue) are also shown. b, solvent-accessible surface of SULT1A1 calculated as described in a, with E2 (magenta) docked into the active site
and with PAPS at the cofactor binding site. As in a, bound pNP1 is shown in orange and pNP2 in blue. E2 atoms clash with Phe247 (in both the x-ray
(gray) and alternate rotamer conformations (pink)), Val148 (gray), and Phe84 (gray). c, superimposition of the structures of SULT1A1 shown in green
(with pNP1 bound, orange) and SULT1E1 shown in pink (with E2 bound, magenta), portraying the striking variation in loop positioning at the
active site. d, solvent-accessible surface of SULT1A1 at the active site, showing the space available for binding pNP1 (orange) and pNP2 (blue). The
position of bound PAP is also shown. e, solvent-accessible surface of SULT1E1 at the active site, showing the space available for binding E2
(magenta). The position of bound PAP is also shown.
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bind to the enzyme. We therefore propose that the substrate
binding site of SULT1A1 is plastic, allowing it to adopt varying
architectures that will accept a wide range of hydrophobic
phenolic compounds including flexible L-shaped molecules and
rigid, planar, multiple ring compounds.
Such SULT1A1 active site plasticity may, in part, be a con-
sequence of a disorder-order transition that we propose occurs
in the enzyme during catalysis. Thus, the substrate binding
regions may be able to adapt to the specific shape of the sub-
strate during the process of binding. Our hypothesis for a
disorder-order transition in SULT1A1 is based on the compar-
ison of the crystal structures of the two human enzymes,
SULT1A1 and SULT1A3 (Fig. 6). The SULT1A3 structure
solved in the absence of cofactor and substrate (10, 16) has a
disordered substrate binding site, whereas the SULT1A1-PAP-
pNP crystal structure complex has an ordered substrate bind-
ing pocket. Although the unliganded structure of SULT1A1 has
not yet been determined experimentally, the very high se-
quence conservation between them suggests that the broad
structural and mechanistic properties of these two enzymes
will also be conserved. Thus, we propose that the apo form of
SULT1A1 has a disordered binding site and that during catal-
ysis the enzyme undergoes a disorder-order transition. There
are now several examples in the literature of disorder-order
transitions occurring during ligand binding or enzymatic catal-
ysis. For example, the type I phosphoribosyltransferase en-
zymes have a flexible loop that moves to cover the active site
during catalysis to protect the transition state from attack by
bulk water (41). Similarly, yeast acetohydroxyacid synthase
(42, 43), yeast pyruvate decarboxylase (44), ribulose-1,5-
bisphosphate carboxylase/oxygenase, and triosephosphate
isomerase (45) have been shown to undergo disorder-order
transitions at the active site.
Although SULT1A1 and SULT1A3 may share a disorder-
order transition because of their high sequence identity, there
is sufficient sequence variation between the two to give rise to
quite distinct substrate preferences. Thus, although both en-
zymes accept simple aromatic phenols as substrates, SULT1A3
prefers these substrates to be positively charged, as in dopa-
mine and tyramine (9). In contrast, dopamine and tyramine are
relatively poor substrates for SULT1A1, whereas uncharged
simple aromatic phenols like pNP, p-cresol, and p-ethylphenol
are excellent substrates (9). Furthermore, SULT1A1 is able to
accept very large lipophilic substrates such as T2, E2, and
polycyclic aromatics, whereas SULT1A3 does not accept these
nearly as well. This distinct difference in substrate preference
may be due to only two residue differences in the active site. As
we have shown, the SULT1A1 active site is extremely hydro-
phobic, and such an environment would clearly be unfavorable
for binding positively charged substrates. However, the size of
the SULT1A1 active site is such that it can accept both simple
and complex lipophilic substrates (Fig. 1). In SULT1A3, two of
the hydrophobic residues of SULT1A1 are replaced with nega-
tively charged residues (Glu146 and Glu89), and these would
favor binding of substrates with positively charged groups
(such as dopamine and tyramine) and discriminate against
very hydrophobic compounds, whether large or small. It would
be interesting to see whether SULT1A3 would accept a more
complex substrate that incorporates a positive charge designed
to interact with the acidic residues.
Genetic variation in SULT1A1 has been linked to various
cancers because of its ability to sulfonate a wide range of
promutagens and procarcinogens. The crystal structure of
SULT1A1 reported here is that of variant SULT1A1*2, which
has a histidine at residue 213 in place of the more commonly
found arginine in SULT1A1*1. The SULT1A1*2 variant is
found in about 30% of Caucasians and is reported as having
decreased activity and lower stability than SULT1A1*1 (32).
This property is thought to contribute to interindividual vari-
ation in sulfonation of substrates and hence to the predisposi-
tion to cancers. For example, one study (8) investigated the
mutagenic activity of two promutagens in a bacterial system
expressing either SULT1A1*1 or SULT1A1*2 at roughly the
same levels. This study showed that expression of SULT1A1*1
gave an 10-fold higher rate of mutation than when
SULT1A1*2 was expressed. What is the structural effect of
replacing Arg213 with His? Although we do not have the struc-
ture of SULT1A1*1 for comparison, we can investigate this by
comparing the structure of SULT1A1*2 with that of SULT1A3,
which has an arginine at position 213. Residue 213 is located
just before the large disordered/flexible region of SULT1A3
(Fig. 2b). In SULT1A1 the histidine at position 213 makes a
FIG. 6. Comparison of SULT1 crystal structures. Structures of
human SULT1A1 complexed with PAP (green), pNP1 (orange), and
pNP2 (blue) (a); human SULT1A3 complexed with sulfate (pink) (b); and
mouse SULT1E1 complexed with PAP (green) and E2 (pink) (c). The
blue regions in the SULT1A1 structure indicate parts of the protein that
are disordered in SULT1A3. The dotted lines indicate disordered re-
gions of SULT1A3 and SULT1E1.
FIG. 7. Proposed structural basis of SULT1A1 polymorphism.
Stereo view of a region of the SULT1A1 structure near Tyr62, showing
the interaction between the His213 side chain (found in SULT1A1*2)
and the backbone of residue Val211. The more common variant of
SULT1A1, SULT1A1*1, has an arginine at position 213, which we
propose interacts with Tyr62 as found in the structure of SULT1A3
(green). The proximity of this region to the PSB loop is shown.
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hydrogen bond interaction with the main chain carbonyl of
residue 211. However, the arginine in SULT1A3 does not form
this interaction. Instead it makes a stacking interaction with
the side chain of Tyr62, forming what appears to be an amino-
aromatic interaction (Fig. 7). Tyr62 is highly conserved in the
SULT1A family. It would be interesting to mutate Tyr62 to a
hydrophobic but nonaromatic residue to investigate whether a
change in the interacting partner of Arg213 would also affect
activity in the bacterial mutagenesis system. The position of
residue 213, just preceding a flexible region that we propose
undergoes disorder-order transition, would explain in part why
mutation of this residue could affect enzyme stability. It is also
worth noting that Tyr62, the proposed partner for Arg213, is
located just before the PSB loop in the enzyme sequence (Fig.
7). This suggests that an alteration in the Tyr62–Arg213 inter-
action could impact on cofactor binding.
In summary, the structure of SULT1A1 reveals an extended
and very hydrophobic binding site, which is consistent with
binding of both small and large phenolic substrates and ex-
plains the observed substrate inhibition with pNP. Binding of
extended rigid substrates like E2 may require active site plas-
ticity and a disorder-order transition, which we propose is
conserved between SULT1A1 and SULT1A3. Furthermore, the
structure of SULT1A1 will now help us to unravel how genetic
variation in this enzyme translates into interindividual varia-
tion in the predisposition cancer.
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